ReviewAdvances in experimental medicine and biology2026
Neurofeedback in Major Depression.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence highlights the significant interplay between mental health and brain health, underscoring the potential of non-pharmacological interventions for major depressive disorder. Brain-computer interfaces offer a promising avenue in psychiatry, advancing self-regulation techniques to elucidate relationships among human behavior, emotional processes, and brain functionality. By visualizing brain function and enabling active modulation of cortical activity through real-time feedback, neurofeedback utilizes signals derived from electroencephalography and/or real-time functional magnetic resonance imaging, providing patients with interactive indicators for self-brain training. This closed-loop system targets specific brain activity or regions known to be associated with depression for upregulation or downregulation, thereby enhancing emotion regulation and executive functioning via mechanisms underlying neuroplasticity. Clinical evidence demonstrates promising outcomes, including strengthened neural connectivity, symptom improvement, and increased remission rates in depression. By coupling the advantages of psychotherapy and neuromodulation, neurofeedback aligns with the field's shift toward personalized, technology-driven psychiatry. This chapter also addresses the practical challenges, including protocol standardization, precision targeting, long-term assessment, and scalable delivery, that are essential for translating promising pilot data into routine clinical practice and for empowering patients to actively engage in their brain health toward mental health improvement.
Indexed as
Identifiers
42036584What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.